Evusheld long-acting antibody combination retains neutralising activity against Omicron variant in independent FDA study
Only antibody authorised in the US for pre-exposure prophylaxis of COVID-19 In this pre-clinical study, Evusheld’s Inhibitory Concentration 50 (IC50), a measure of neutralising potency of an antibody, was 171 ng/ml and 277 ng/ml in two confirmatory tests, which is within the Read More …
